Check out your Company Bowl for anonymous work chats.
We successfully hosted the sixth edition of the Barcelona MBA Day, providing MBA students with an exclusive look into our operations and culture. As part of Barcelona Global's initiative to position Barcelona as a leading hub for innovation and industry, this event highlighted Grifols’ vital role in the local economy and our dedication to attracting top talent. Throughout the day, students had the opportunity to tour our facilities, learn about the company's mission and products, and network with industry professionals. This provided valuable insights into the biopharma industry and potential career paths. We are thrilled to be part of this initiative that strengthens Barcelona’s reputation and nurtures future leaders. #GrifolsTalent #MBADay
Es un orgullo recibir este reconocimiento como #DiversityLeadingCompany 2024. Fomentar la diversidad y la inclusión nos permite crear equipos más competitivos, fuertes e innovadores para servir mejor a nuestros donantes, pacientes y clientes. #WeAreGrifols
We are proud to be named one of TIME Magazine’s ‘World’s Best Companies’ list for the second year in a row. Grifols climbs sharply to land in the top-third of the publication’s ranking of the 1,000 highest-performing companies, up 393 positions from last year. This steep ascent reflects the company’s relentless commitment to employee satisfaction, revenue growth and sustainability. Camille Alpi, Grifols Chief Human Resources & Talent Officer, highlights that this achievement is “a testament not only to the hard work and dedication of our employees but also to our long-term vision to lead with integrity and responsibility”. #WorldsBestCompanies #GrifolsTeam
Nos alegra dar la bienvenida a una nueva promoción de becarios y becarias. 👩🎓 👨🎓 25 estudiantes de FP Dual se han unido al equipo en Parets del Vallés (Barcelona) para aprender y adquirir experiencia en distintos campos dentro del área técnica y de producción de medicinas derivadas del plasma. Esto es solo el principio de vuestro viaje en el sector farmacéutico, y estamos aquí para apoyar vuestro crecimiento en cada paso del camino. 🎉 ¡Bienvenidos a Grifols! #GrowWithUs #WeAreGrifols
🚀 The GROW Program is an 8-month initiative empowering high-potential employees through coaching, development sessions, and mentorship. Recent in-person sessions in Los Angeles and Barcelona focused on self-leadership, connection-building, and innovation, featuring a Leadership Panel in LA and a workshop in Barcelona. At Grifols, developing our people is vital to our strategic vision.
On World Cleanup Day, our global teams took inspiring action for the environment. In China, 48 employees from Beijing and Shanghai joined Pick Up China to clean mountain trails in Anji, collecting 40 kg of waste and 900 recyclable items. Across the U.S., teams from 10 plasma centers and sites in San Diego and Clayton participated in clean-ups to promote responsible waste disposal. These efforts are part of a global movement to protect our planet and raise awareness about waste's impact on ecosystems. We're proud to support this initiative, now recognized as an International Day by the United Nations. #WorldCleanupDay #Sustainability #WhatWeDoMatters
Click to APPLY
Grifols today announced it has acquired 10% of Bloodbuy, a cloud-based marketplace that facilitates buying and selling of blood components in the U.S. Bloodbuy?s proprietary technology platform and computer-based algorithms enable regional blood-collection centers to expand their customer base across the U.S., while providing hospitals and other healthcare providers greater access to vital blood components, efficiently and efficaciously connecting supply and demand. The investment forms part of Grifols? ongoing commitment to leading technologies and solutions that reinforce and complement its core businesses. Bloodbuy will offer synergies to Grifols? Bio Supplies Division and its Diagnostic Division?s leading transfusion medicine business.
Grifols to acquire Green Cross’ Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers, for a total amount of US$460 million. Grifols will become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year. The transaction is part of Grifols’ sustainable global growth strategy to ensure patients worldwide have safe and secure access to life-saving plasma-derived medicines. Furthermore, the operation aligns with Grifols’ commitment to helping countries reach self-sufficiency of life-sustaining plasma-derived medicines.
Grifols today announced the beginning of the production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. Grifols continues to lead initiatives to combat COVID-19 with the development of the first specific drug. Grifols is leading the production of this potential anti-COVID-19 passive immune therapy as part of a collaboration with U.S. health authorities. For more information please see the press release.
